Ashraf Eassa
Long/short equity, contrarian, independent research, tech

Applied Micro: Yet More Skepticism Required

Applied Micro's (NASDAQ:AMCC) management appears to believe that it can pull the wool over investors' eyes regarding its fabled X-Gene strategy indefinitely. Unfortunately, as I listened to the Q&A, none of my criticisms of the Applied Micro executive team were quelled. In fact the vague, PR-like responses to questions regarding its upcoming "X-Gene" product lend further credibility to my case that at the end of the day, X-Gene will be a textbook example of "over promise, under deliver."

Brushing Off The Intel Threat

Consider the following question posed by Patrick Wang of Evercore Partners from the latest conference call,

When we take a look at X Gene over the course of this year you'll have a 40-nanometer...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details